Welcome

Mylan, Pfizer Dodge Pharmacy Chain’s EpiPen Price-Gouging Claims

July 27, 2021, 8:01 PM

Mylan NV and Pfizer Inc. tentatively dodged federal antitrust claims brought in Kansas by a pharmacy chain over their alleged scheme to gouge EpiPen purchasers, three days after a judge tentatively approved Pfizer’s $345 million deal to exit a related multidistrict case.

The same judge, Daniel D. Crabtree, dismissed the lawsuit by Kinney Drugs Inc., saying the upstate New York retail business lacked standing to accuse the pharmaceutical companies of wide-ranging regulatory gamesmanship aimed at cornering the market for lifesaving allergy injections.

Crabtree acknowledged that drug distribution giant McKesson Corp. had assigned certain antitrust claims to Kinney. But the assignment ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.